Health Condition 1: E116- Type 2 diabetes mellitus with other specified complications
Conditions
Interventions
Intervention1: Nil: Nil
Intervention2: Nil: Nil
Intervention3: Nil: Nil
Control Intervention1: atorvastatin: patients who are already on 10-20 mg atorvastatin given per oral OD in the night for 18 mon
Sponsors
AIIMS Mangalagiri
Eligibility
Inclusion criteria
Inclusion criteria: Participant age must be above 40 years Previously diagnosed case of type 2 diabetes mellitus Participants must currently be either on atorvastatin or rosuvastatin for atleast 1.5 yrs (18 months or more) Participants who have given written informed consent for the study
Exclusion criteria
Exclusion criteria: Patients with a known case of any bone-related diseases (e.g., osteoporosis, osteopenia) Patients who are already on any bone-modifying medications (e.g., SGLT-2 Inhibitors, thiazolidinediones, insulin, bisphosphonates, calcium and vitamin D supplementation) Patient who are having a history of any uncontrolled chronic disorder ? renal, liver disease Post menopausal women Pregnant and breastfeeding women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| This study will help to identify the effects and potential differences between atorvastatin and rosuvastatin on bone health parameters like bone mineral density and bone forming marker - P1NP in patients with type 2 diabetes mellitus. The research will also give an insight on how the duration and doses of the medications create an impact on overall health of the bone.Timepoint: Being a cross-sectional study, the outcomes namely BMD and P1NP will be measured once at the time of enrolment in patients who have been taking Atorvastatin or Rosuvastatin for 18 months or more. | — |
Secondary
| Measure | Time frame |
|---|---|
| nilTimepoint: nil | — |
Countries
India
Contacts
Public ContactDr Shilpa P
AIIMS Mangalagiri
Outcome results
None listed